drugset / Trial / NCT00671125

Study of Efficacy of Ramelteon in Adults With Chronic Insomnia

NCT00671125

Phase 3 Completed 405 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of Ramelteon, once daily (QD), in the treatment of chronic insomnia using polysomnography and subjective measures of sleep

Timeline

Start
2003-01
Primary completion
2003-09
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramelteon Unknown 8 mg Oral
Subject Ramelteon Unknown 16 mg Oral

Indications